Still, in an editorial that accompanied two JAMA studies, experts urged “continued vigilance” to ensure GLP-1 drugs don’t worsen problems in people with preexisting mental health conditions.

Regulators in the U.S. and Europe recently determined that a popular group of drugs for weight loss and diabetes don’t heighten the risk of suicide. New data published in the Journal of the American Medical Association on Tuesday appear to back up those assessments, though researchers cautioned that there’s still more work to be done.